Two companies spent two decades proving that robotic legs could put people back on their feet. On 1 October, one of them bought the other. The pioneer that came first is the one that ended up on the balance sheet.
Wandercraft, a Paris robotics firm founded in 2012, acquired Ekso Bionics from a subsidiary of ChronoScale Holdings (Nasdaq: CHRN). Both boards approved the transaction. It was signed and closed on the same day, and no price was disclosed. The combined company claims to be the largest medical-exoskeleton business in the world, with products reaching more than 700 rehabilitation centres.
The logic is not subtle. This category was never big enough to carry two independent survivors. What Wandercraft is buying reaches further than a product line: it is the United States clinical footprint that a European hardware company cannot assemble from scratch.
Combined clinical footprint
Atalante X and EksoNR together, under shared US Food and Drug Administration (FDA) clearances and CE marking. · Wandercraft, 2026
What was actually sold
Ekso Bionics, Inc. left the hands of a subsidiary of ChronoScale Holdings and went to Wandercraft. The two companies describe the deal as unanimous at board level and simultaneous at signature. Financial terms stay private. In practice that means the market gets a transaction without a multiple, which is unusual for a deal positioned as a category-defining combination.
The buyer's own language gives more away than the press release format suggests. Wandercraft talks about an end-to-end continuum of care: rehabilitation first, everyday personal mobility second. That phrase is a product roadmap, not a courtesy. It says the company intends to sell across the whole arc of a patient's recovery, from the clinic bench to the front door.
Matthieu Masselin, CEO and co-founder of Wandercraft, framed the combination as a shared vision:
We share a vision for how robotics can empower people whose mobility has been unfairly limited by injury or disease.— Matthieu Masselin, CEO and co-founder, Wandercraft
Read commercially, the sentence means Wandercraft now owns relationships it could not have bought one clinic at a time.
Why Ekso could not stay independent
The San Francisco Business Times records that Ekso pioneered robotic exoskeletons for medical use.
The San Francisco Business Times reported years of red ink and a corporate restructuring before the sale.
The transaction ran through a ChronoScale subsidiary, not through an operating-company board acting alone.
Tracxn records Ekso's last disclosed round in 2014, and shows no later financing in its tracked history.
Those four facts describe a company that solved the engineering problem and never solved the commercial one. Medical exoskeletons are reimbursement-dependent devices sold to rehabilitation departments with fixed budgets. The buyer is a hospital. The decision cycle is long. The unit volume is small. The device sits in a therapy gym and earns its keep in sessions, not in shipments.
A business like that needs either a very large balance sheet or a very cheap cost base. Ekso had neither after the losses accumulated. It had the clinical record, the clearances and a place in the literature. What it did not have was the runway to keep converting those advantages into orders.
The wider category has been signalling a comeback. As we wrote in September, the component bet around lightweight exoskeletons is what revives a market investors had written off. Components are cheaper than finished devices, and cheaper components lower the barrier for everyone building on top of them. Ekso's problem was never that exoskeletons stopped working.
What Wandercraft brings to the combination
Wandercraft arrived with a different shape of business. Its Eve device is an FDA-cleared personal exoskeleton for hands-free upright mobility at home. Its Atalante X is a clinical platform used in more than 150 rehabilitation and research centres. Add Ekso's EksoNR and Indego Personal and the combined catalogue covers both ends of the market in a single portfolio.
| Parameter | Wandercraft | Ekso Bionics |
|---|---|---|
| Personal device | ✔ Eve — hands-free, self-balancing, home use | ✔ Indego Personal — modular wearable |
| Clinical device | ✔ Atalante X — 150+ rehabilitation and research centres | ✔ EksoNR — established US clinical base |
| Indications | ◐ Stroke, spinal cord injury, multiple sclerosis, acquired brain injury | ◐ Identical list under shared clearances |
| Industrial systems | ✔ Calvin-40 autonomous humanoid | ✗ Not part of the catalogue |
| Market position | ◐ Strong in Europe, the Middle East and Africa (EMEA), thinner US clinical reach | ✔ Deep US clinical relationships |
Product lines as described by both companies, October 2026
Two rows in that table do the work. The indications row shows how little product overlap there actually is: both companies cleared the same four conditions, which means the combination removes a competitor from a shared reimbursement code rather than buying a new one. The industrial row shows what Wandercraft has that Ekso never attempted.
Wandercraft gains US clinical distribution it could not have built domestically, and it gains it under existing clearances rather than a fresh regulatory path.
The industrial humanoid programme gets funded by clinical revenue instead of venture capital alone.
What the consolidation actually means
Medical robotics does not consolidate the way software does. There is no network effect to acquire and no install base that flips automatically. What consolidates is distribution: sales teams, clinical advisors, tender history, service engineers who can calibrate a device on site. Those assets are geography-bound and slow to build, which makes buying them the rational move for a company entering a new region.
Wandercraft's stated position is strength in EMEA with thinner reach into the United States. Ekso's stated position is the opposite. Neither claim is verifiable from outside the companies, but the structure of the deal is consistent with it. A buyer paying an undisclosed price for a company with a reported history of losses is usually paying for something other than earnings.
The strategic question is whether the combined business can convert 700 rehabilitation centres into a single commercial operation. Centres do not merge. Contracts do not merge. A clinician trained on EksoNR does not automatically treat Atalante X as a substitute. Integration in device businesses is measured in sales cycles, not quarters, and the first evidence will appear in whether the combined company keeps both catalogues or quietly retires one of them.
There is a second, quieter consequence. With Ekso absorbed, the field of independent medical-exoskeleton companies shrinks again. Fewer independent suppliers means fewer price references for hospital procurement, which tends to help the incumbent with the broader catalogue. The company that could not stay independent also removes the benchmark everyone else priced against.
Wandercraft still has to prove that clinical revenue can carry an industrial ambition. That is the part of the story the acquisition did not answer, and it is where the next round of financing will point.
The humanoid sitting next to the deal
Wandercraft describes Calvin-40 as an autonomous humanoid built for heavy lifting and difficult-to-staff work. It sits in the same company as Eve and Atalante X, which is an unusual pairing: a home mobility device, a hospital platform and an industrial humanoid under one engineering roof.
The acquisition makes the pairing legible. Clinical exoskeletons generate regulated, repeatable revenue and a regulatory record that compounds. Industrial humanoids consume capital and produce pilots. A company that owns both can fund the second with the first, provided the first actually scales after integration.
Exoskeletons and humanoids share actuation, balance control and safety certification. The expensive part of both is proving that a machine can carry a human weight without hurting anyone.
That shared engineering base is the argument for keeping the industrial programme inside a medical company. It is also the argument a sceptical board would push back on, because clinical customers and warehouse operators buy on completely different logic.
What has to be true next
Will the combined company become the default supplier in its category?
Probability: 55% — duplicate catalogues are expensive to maintain, and the indications overlap almost completely.
✅ Arguments for
An undisclosed price on a loss-making target usually signals a strategic rather than financial buyer, which favours integration over autonomy.
Confirmation criteria: a joint product roadmap published within twelve months, or a named facility converting from one platform to the other.
❌ Arguments against
Undisclosed terms hide whether Wandercraft took on liabilities that constrain the industrial programme.
Falsification criteria: both platforms still marketed separately with no shared roadmap twenty-four months after close.
Whether EksoNR and Atalante X continue under separate names after integration.
Any disclosure of the purchase price, or of liabilities assumed from ChronoScale.
Reimbursement decisions that cover both platforms, rather than one.
Calvin-40 moving from demonstration to a named industrial customer.
Scenarios to 2028
🟢 Integrated leader (40%)
Consequence: the category has a clear leader, and hospital procurement negotiates with one supplier.
🟡 Two catalogues, one balance sheet (45%)
Consequence: a larger company with the same margin profile as the two it replaced.
🔴 Integration stalls (15%)
Consequence: the industrial humanoid becomes the first programme cut.